Several antibodies were found to deplete T-reg cells including basiliximab, a chimeric anti-CD25 monoclonal antibody, which was first tested in kidney transplant patients and showed a transitional loss of FOXP3+ and FOXP3− CD25+ T-cells in the circulation [125]. This evidence concerns the gene FOXP3 and medical procedure.